Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05724108 |
|
Recruitment Status :
Recruiting
First Posted : February 13, 2023
Last Update Posted : September 13, 2023
|
Sponsor:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
National Cancer Institute (NCI)
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Metastatic Neuroendocrine Tumor | Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Lutetium Lu 177 Dotatate Procedure: Magnetic Resonance Imaging Drug: Triapine | Phase 2 |
PRIMARY OBJECTIVE:
I. To evaluate the overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of combination triapine + lutetium Lu 177 dotatate and standard of care lutetium Lu 177 dotatate alone.
SECONDARY OBJECTIVE:
I. To evaluate progression-free survival (PFS) in study and control arm.
EXPLORATORY OBJECTIVES:
I. To evaluate plasma hPG80 as a biomarker of treatment response. II. To evaluate plasma deoxyribonucleosides as a biomarker of triapine resistance.
III. Collect plasma for circulating deoxyribonucleic acid (DNA) (ctDNA) assessment.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive lutetium Lu 177 dotatate intravenously (IV) on study. Patients also undergo computed tomography (CT) and/or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial.
GROUP II: Patients receive lutetium Lu 177 dotatate IV and triapine orally (PO) on study. Patients also undergo CT and/or MRI and collection of blood samples throughout the trial.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 94 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors |
| Estimated Study Start Date : | December 10, 2023 |
| Estimated Primary Completion Date : | January 1, 2025 |
| Estimated Study Completion Date : | January 1, 2025 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Group I (lutetium Lu 177 dotatate)
Patients receive lutetium Lu 177 dotatate IV on study. Patients also undergo CT and/or MRI and collection of blood samples throughout the trial.
|
Procedure: Biospecimen Collection
Undergo collection of blood samples
Other Names:
Procedure: Computed Tomography Undergo CT
Other Names:
Drug: Lutetium Lu 177 Dotatate Given IV
Other Names:
Procedure: Magnetic Resonance Imaging Undergo MRI
Other Names:
|
|
Experimental: Group II (lutetium Lu 177 dotatate, triapine)
Patients receive lutetium Lu 177 dotatate IV and triapine PO on study. Patients also undergo CT and/or MRI and collection of blood samples throughout the trial.
|
Procedure: Biospecimen Collection
Undergo collection of blood samples
Other Names:
Procedure: Computed Tomography Undergo CT
Other Names:
Drug: Lutetium Lu 177 Dotatate Given IV
Other Names:
Procedure: Magnetic Resonance Imaging Undergo MRI
Other Names:
Drug: Triapine Given PO
Other Names:
|
Primary Outcome Measures :
- Overall response rate [ Time Frame: Up to 5 years ]Estimated along with exact 95% binomial confidence intervals in each arm and compared between arms using the z-test statistic.
Secondary Outcome Measures :
- Progression free survival (PFS) [ Time Frame: Time from the date of randomization to the date of first documented progression or death due to any cause, assessed up to 5 years ]Progression will be measured by Response Evaluation Criteria in Solid Tumors 1.1 criteria. Log-rank test will be used to compare PFS between treatment and control. Median survival time and the corresponding confidence intervals will be calculated by the Kaplan-Meier Method.
Other Outcome Measures:
- Plasma hPG80 [ Time Frame: Up to 5 years ]Analysis of variance will be used to analyze plasma hPG80 concentration. Baseline plasma hPG80 will be used as covariate. F-test and t-test will be conducted to test the differences in hPG80 change between treatment arms and responses.
- Plasma deoxyribonucleosides [ Time Frame: Pre- to post-triapine administration ]Will evaluate plasma deoxyribonucleosides as a biomarker of triapine resistance. Pre and post triapine administration changes in deoxyribonucleosides will be analyzed by pair-wise t-test, stratified by study arm. Secondary and exploratory analysis on repeatedly measured deoxyribonucleosides will entail a linear mixed model for comparison between treatment groups.
- Circulating deoxyribonucleic acid (ctDNA) [ Time Frame: Up to 5 years ]ctDNA will be analyzed by summary descriptive statistics as well as visualization graphics such as heat maps. Data processing and downstream data analysis pipelines for the genomic data will be performed including differential analysis for comparison of genomic data between arms using the limma package in R/Bioconductor with adjustment for false discovery rate.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients must have metastatic, histologically confirmed well-differentiated neuroendocrine tumor with positive gallium 68 DOTATATE or copper 64 DOTATATE scan. Lesions on dotatate scan will be considered positive if the standardized uptake volume maximum (SUVmax) of target lesion is > 2 times standardized uptake value (SUV) mean of normal liver parenchyma. Patients with lung neuroendocrine tumors (NETs) are excluded from the trial
- Patients must have progressive disease based on RECIST criteria, version 1.1 evidenced with CT scans/MRI obtained within 24 months from enrollment
- Patients must have measurable disease per RECIST 1.1
- Failure of at least one prior systemic cancer treatment with somatostatin analogs
- No prior exposure to peptide receptor radionuclide therapy
- Recovered from adverse events of previously administered therapeutic agents (i.e., to grade 2 or less toxicity) according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0
-
Age >= 18 years
- Because no dosing or adverse event data are currently available on the use of triapine in combination with lutetium Lu 177 dotatate in patients < 18 years of age, children are excluded from this study
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
- Serum creatinine =< 1.5 x institutional ULN. Creatinine > 1.5 ULN will require a measured creatinine clearance (CrCl) > 50 ml/min to qualify
- Hemoglobin > 5.0 mmol/L (> 8.0 g/dL)
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with treated brain metastases and off steroids are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression for at least 4 weeks prior to enrollment in the study. Patients with a history of brain metastases must have a head CT with contrast to document stable disease prior to enrollment in the study
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
- Pregnancy precaution: Men and women should avoid pregnancy for seven months after the date of their last treatment with lutetium Lu 177 dotatate. It is noteworthy that beta-human chorionic gonadotropin (beta-HCG) may be secreted by a small percentage of NETs, such that, in addition to being a pregnancy marker, it also is a tumor marker. Consequently, NET female patients with positive beta-HCG (> 5 mIU/mL) at baseline can be eligible to enter the study and receive treatment if pregnancy can be excluded by lack of expected doubling of beta-HCG and negative pelvic ultrasound. Normally, in pregnant subjects beta-HCG doubles every 2 days during the first 4 weeks of pregnancy and every 3.5 days by weeks 6 to 7. Women of childbearing potential include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral ovariectomy) or is not postmenopausal (defined as amenorrhea > 12 consecutive months, and for women on hormone replacement therapy, only with a documented plasma follicle-stimulating hormone [FSH] level > 35 mIU/mL). Even women who are using oral, implanted, or injected contraceptive hormones, an intrauterine device (IUD), or barrier methods (diaphragm, condoms, spermicidal) to prevent pregnancy, are practicing abstinence or where the partner is sterile (e.g., vasectomy) should be considered to be of childbearing potential. Postmenopausal women who have fertilized eggs implanted are also considered to be of childbearing potential. Acceptable methods of contraception may include total abstinence at the discretion of the Investigator in cases where the age, career, lifestyle, or sexual orientation of the patient ensures compliance. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Reliable contraception (hormonal or barrier method of birth control; abstinence) should be maintained throughout the study and for 7 months after study treatment discontinuation. All men and women of childbearing potential and male partners must use a double-barrier method of birth control or practice continuous abstinence from heterosexual contact throughout the study and for seven months after the end of the last treatment
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients who have not recovered from adverse events of previously administered therapeutic agents (i.e., have residual toxicities > grade 2) according to CTCAE 5.0, with the exception of alopecia
- Patients who are receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or lutetium Lu 177 dotatate
- Patients with uncontrolled intercurrent illness
- Uncontrolled congestive heart failure (New York Heart Association [NYHA] III, IV)
- Pregnant women are excluded from this study because triapine is a ribonucleotide reductase (RNR) inhibitor and lutetium Lu 177 dotatate is a peptide receptor radionuclide therapy with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with triapine and lutetium Lu 177 dotatate, breastfeeding should be discontinued if the mother is treated with triapine and lutetium Lu 177 dotatate and for 2.5 months following the last treatment
- Inability to swallow oral medications or gastrointestinal disease limiting absorption of oral agents
- Patients with any other significant condition, currently uncontrolled by treatment, which may interfere with completion of the study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05724108
Locations
| United States, California | |
| University of California Davis Comprehensive Cancer Center | Recruiting |
| Sacramento, California, United States, 95817 | |
| Contact: Site Public Contact 916-734-3089 | |
| Principal Investigator: Edward J. Kim | |
| United States, Florida | |
| UM Sylvester Comprehensive Cancer Center at Aventura | Recruiting |
| Aventura, Florida, United States, 33180 | |
| Contact: Site Public Contact 954-461-2180 | |
| Principal Investigator: Aman Chauhan | |
| UM Sylvester Comprehensive Cancer Center at Coral Gables | Recruiting |
| Coral Gables, Florida, United States, 33146 | |
| Contact: Site Public Contact 305-243-2647 | |
| Principal Investigator: Aman Chauhan | |
| UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Recruiting |
| Deerfield Beach, Florida, United States, 33442 | |
| Contact: Site Public Contact 305-243-2647 | |
| Principal Investigator: Aman Chauhan | |
| University of Miami Miller School of Medicine-Sylvester Cancer Center | Recruiting |
| Miami, Florida, United States, 33136 | |
| Contact: Site Public Contact 305-243-2647 | |
| Principal Investigator: Aman Chauhan | |
| UM Sylvester Comprehensive Cancer Center at Kendall | Recruiting |
| Miami, Florida, United States, 33176 | |
| Contact: Site Public Contact 305-243-2647 | |
| Principal Investigator: Aman Chauhan | |
| UM Sylvester Comprehensive Cancer Center at Plantation | Recruiting |
| Plantation, Florida, United States, 33324 | |
| Contact: Site Public Contact 305-243-2647 | |
| Principal Investigator: Aman Chauhan | |
| United States, Illinois | |
| Northwestern University | Recruiting |
| Chicago, Illinois, United States, 60611 | |
| Contact: Site Public Contact 312-695-1301 cancer@northwestern.edu | |
| Principal Investigator: Al B. Benson | |
| United States, Kentucky | |
| University of Kentucky/Markey Cancer Center | Recruiting |
| Lexington, Kentucky, United States, 40536 | |
| Contact: Site Public Contact 859-257-3379 | |
| Principal Investigator: Lowell B. Anthony | |
| United States, Ohio | |
| Ohio State University Comprehensive Cancer Center LAO | Recruiting |
| Columbus, Ohio, United States, 43210 | |
| Contact: Lowell B. Anthony lowell.anthony@uky.edu | |
| Principal Investigator: Lowell B. Anthony | |
| Ohio State University Comprehensive Cancer Center | Recruiting |
| Columbus, Ohio, United States, 43210 | |
| Contact: Site Public Contact 800-293-5066 Jamesline@osumc.edu | |
| Principal Investigator: Bhavana Konda | |
| United States, Pennsylvania | |
| University of Pittsburgh Cancer Institute (UPCI) | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15232 | |
| Contact: Site Public Contact 412-647-8073 | |
| Principal Investigator: Janie Y. Zhang | |
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Lowell B Anthony | Ohio State University Comprehensive Cancer Center LAO |
| Responsible Party: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT05724108 |
| Other Study ID Numbers: |
NCI-2023-01224 NCI-2023-01224 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 10558 ( Other Identifier: Ohio State University Comprehensive Cancer Center LAO ) 10558 ( Other Identifier: CTEP ) UM1CA186712 ( U.S. NIH Grant/Contract ) |
| First Posted: | February 13, 2023 Key Record Dates |
| Last Update Posted: | September 13, 2023 |
| Last Verified: | September 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page. |
| URL: | https://grants.nih.gov/policy/sharing.htm |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms |
Neoplasms, Nerve Tissue Lutetium Lu 177 dotatate Molecular Mechanisms of Pharmacological Action Radiopharmaceuticals |